- Home
- PTHL vs CXAI Comparison
PTHL vs CXAI Comparison
Compare PTHL & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- CXAI
- Stock Information
- Founded
- PTHL 1998
- CXAI N/A
- Country
- PTHL China
- CXAI United States
- Employees
- PTHL N/A
- CXAI N/A
- Industry
- PTHL
- CXAI EDP Services
- Sector
- PTHL
- CXAI Technology
- Exchange
- PTHL Nasdaq
- CXAI Nasdaq
- Market Cap
- PTHL 13.5M
- CXAI 16.0M
- IPO Year
- PTHL 2024
- CXAI N/A
- Fundamental
- Price
- PTHL $1.02
- CXAI $0.73
- Analyst Decision
- PTHL
- CXAI
- Analyst Count
- PTHL 0
- CXAI 0
- Target Price
- PTHL N/A
- CXAI N/A
- AVG Volume (30 Days)
- PTHL 1.9M
- CXAI 666.7K
- Earning Date
- PTHL 01-01-0001
- CXAI 08-12-2025
- Dividend Yield
- PTHL N/A
- CXAI N/A
- EPS Growth
- PTHL N/A
- CXAI N/A
- EPS
- PTHL N/A
- CXAI N/A
- Revenue
- PTHL $448,196.00
- CXAI $6,548,000.00
- Revenue This Year
- PTHL N/A
- CXAI N/A
- Revenue Next Year
- PTHL N/A
- CXAI $60.00
- P/E Ratio
- PTHL N/A
- CXAI N/A
- Revenue Growth
- PTHL N/A
- CXAI N/A
- 52 Week Low
- PTHL $0.51
- CXAI $0.61
- 52 Week High
- PTHL $32.00
- CXAI $2.54
- Technical
- Relative Strength Index (RSI)
- PTHL 30.37
- CXAI 39.80
- Support Level
- PTHL $0.70
- CXAI $0.61
- Resistance Level
- PTHL $1.18
- CXAI $0.83
- Average True Range (ATR)
- PTHL 0.15
- CXAI 0.05
- MACD
- PTHL 0.68
- CXAI -0.01
- Stochastic Oscillator
- PTHL 76.30
- CXAI 50.51
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.